Results dissemination of registered clinical trials across Polish academic institutions : a cross-sectional analysis by Strzebońska, Karolina et al.
1Strzebonska K, et al. BMJ Open 2020;10:e034666. doi:10.1136/bmjopen-2019-034666
Open access 
Results dissemination of registered 
clinical trials across Polish academic 
institutions: a cross- sectional analysis
Karolina Strzebonska   ,1 Mateusz T Wasylewski   ,1 Lucja Zaborowska,1 
Nico Riedel   ,2 Susanne Wieschowski   ,3 Daniel Strech   ,2,4 
Marcin Waligora   1
To cite: Strzebonska K, 
Wasylewski MT, Zaborowska L, 
et al.  Results dissemination 
of registered clinical trials 
across Polish academic 
institutions: a cross- 
sectional analysis. BMJ Open 
2020;10:e034666. doi:10.1136/
bmjopen-2019-034666
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
034666).
Received 30 September 2019
Revised 19 December 2019
Accepted 20 December 2019
1REMEDY, Research Ethics 
in Medicine Study Group, 
Department of Philosophy and 
Bioethics, Jagiellonian University 
Medical College, Krakow, Poland
2QUEST Center for Transforming 
Biomedical Research, Berlin 
Institute of Health, Berlin, 
Germany
3Institute for Ethics, History 
and Philosophy of Medicine, 





Dr Marcin Waligora;  
 m. waligora@ uj. edu. pl
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
Strengths and limitations of this study
 ► Our analysis is the first study on the dissemination 
rates of clinical trial findings in Poland, an important 
clinical trial spot in the Central and Eastern Europe.
 ► For each included academic medical centre (AMC) 
trial, search for a publication was done independent-
ly by two researchers in a 4- step process involving 
ClinicalTrials.gov, PubMed, Google Scholar and Web 
of Science.
 ► We show the dissemination rates following both pri-
mary completion date and completion date.
 ► Included studies may represent only a fraction of 
clinical trials performed in Poland—our results may 
be underestimated.
 ► For identifying studies conducted in Polish AMCs we 
relied on the names of AMCs and teaching hospitals 
provided on the ClinicalTrials.gov website.
ABSTRACT
Objectives To establish the rates of publication and 
reporting of results for interventional clinical trials across 
Polish academic medical centres (AMCs) completed 
between 2009 and 2013. We aim also to compare the 
publication and reporting success between adult and 
paediatric trials.
Design Cross- sectional study.
Setting AMCs in Poland.
Participants AMCs with interventional trials registered on  
ClinicalTrials. gov.
Main outcome measure Results reporting on  
ClinicalTrials. gov and publishing via journal publication.
Results We identified 305 interventional clinical trials 
registered on  ClinicalTrials. gov, completed between 2009 
and 2013 and affiliated with at least one AMC. Overall, 243 
of the 305 trials (79.7%) had been published as articles or 
posted their summary results on  ClinicalTrials. gov. Results 
were posted within a year of study completion and/or 
published within 2 years of study completion for 131 trials 
(43.0%). Dissemination by both posting and publishing 
results in a timely manner was achieved by four trials 
(1.3%).
Conclusions Our cross- sectional analysis revealed 
that Polish AMCs fail to meet the expectation for timely 
disseminating the findings of all interventional clinical 
trials. Delayed dissemination and non- dissemination of 
trial results negatively affects decisions in healthcare.
BACkgROunD
The results of completed clinical trials are 
crucial for decision- making in evidence- based 
medicine.1–5 They also inform patients,5 6 
clinicians, researchers, policy- makers,5 impact 
future research5–7 and play an important role 
in health technology assessment.8 9 Non- 
dissemination or delayed dissemination of 
trial findings not only negatively affects deci-
sions in healthcare, but is also unethical as 
the results of all research involving human 
subjects must be publicly available regard-
less of whether they are considered positive 
or negative.6 10 11 Not reporting trials’ results 
is unfair to trial participants who often put 
themselves at risk and burden to contribute 
to scientific knowledge. Paediatric trials 
are particularly challenging as they recruit 
children, thus additional protections are 
required to avoid their exploitation in the 
research.12–14
The statement on public disclosure of 
results from clinical trials published in 2015 
by WHO defines reporting timeframes and 
calls for publication of the results of still 
unpublished trials. The key outcomes of 
clinical trials are to be posted in the results 
section of the clinical trial registry within 12 
months of primary study completion (the 
last visit of the last subject for collection of 
data on the primary outcome) and the main 
findings of clinical trials should be published 
in a peer- reviewed journal (preferably free 
to access) at most within 24 months of study 
completion.15 However, compliance with 
this and similar requirements16–19 has been 
poor.20 21 Still about 50% of completed trials 
remain unreported22 or delay sharing their 
results.20 In the European Union, 89% of 
trials completed between 2004 and 2018 
sponsored by academic institutions were not 
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reported within a year of the trial’s end20 which indicates 
that the academic community failed to meet require-
ments of the European Commission guideline17 and the 
Clinical Trial Regulation EU No.536/2014.19
Even though the problem of under- reporting has been 
widely discussed and many attempts have been made to 
urge dissemination of trial findings at the international 
level, the concept of benchmarking the reporting of clin-
ical trials across academic institutions at the country level 
is emerging.21 23–25
In this study, we aim to establish the rates of publica-
tion and reporting of results for interventional clinical 
trials across Polish academic medical centres (AMCs) 
completed between 2009 and 2013. We also want to 
compare the publication and reporting success between 
adult and paediatric trials.
MeThODS
Our protocol was prospectively posted on the Open 
Science Framework (OSF) website (https:// osf. io/ 
w4pfj/). We adapted methods used previously in similar 
studies.21 23
Retrieval of trials
Interventional clinical trials conducted across Polish 
AMCs completed between 2009 and 2013 were identified 
in  ClinicalTrials. gov database. The complete Aggregate 
Analysis of  ClinicalTrials. gov (AACT) dataset was down-
loaded from http:// aact. ctti- clinicaltrials. org/ on 10 
August 2018. We performed the search of  ClinicalTrials. 
gov instead of EU Clinical Trials Register as our prelimi-
nary search for the same inclusion criteria resulted in 3505 
records identified at the  ClinicalTrials. gov and only 1312 
at the EU Clinical Trials Register. Moreover, EU Clinical 
Trials Register unfortunately do not allow to perform a 
search including primary completion date (CD) and CD 
of registered trials.
Inclusion and exclusion criteria
We define an AMC as a medical university or an academic 
medical institution with clustered teaching hospital/s. 
There are nine medical universities, three universities 
with a medical college and one Center of Postgraduate 
Medical Education, all affiliated with at least one teaching 
hospital in Poland. The search terms used for identifica-
tion of clinical trials across 13 Polish AMCs are available 
on the OSF (https:// osf. io/ bsp3r/).
An R script was used to combine datasets and restrict 
our resulting dataset to studies with a CD between 2009 
and 2013 as well as to exclude observational studies. 
Only studies with the status ‘Completed’, ‘Terminated’, 
‘Suspended’ or ‘Unknown’ were included. After the auto-
matic filtering for the AMCs and city names, the correct 
assignment of studies to the AMCs was verified manually 
by two researchers independently (KS, LZ).
A given trial was assigned to an AMC if the AMC was 
either mentioned as the responsible party, lead sponsor 
or collaborator or if the principal investigator, study chair 
or study director was affiliated with the AMC. The AMC 
was then considered a ‘lead’ contributor in these trials. 
If AMC was mentioned only as a facility or a study was 
conducted in an academic hospital or the principal inves-
tigator, study chair or study director was affiliated only 
with an academic hospital without the name of the AMC, 
then AMC was considered a ‘facility’ contributor in these 
trials. One trial could be counted for multiple AMCs. 
The flow chart presenting the trial selection process with 
reasons for exclusion is shown in online supplementary 
figure 1.
Data extraction
An R script was used to extract the trial characteristics 
from the AACT dataset. For included studies researchers 
checked  ClinicalTrials. gov whether summary results were 
posted or submitted as of 4 December 2018 (KS, MTW).
Publication search
For each of the included studies, search for a publica-
tion was done independently by two researchers (KS, 
MTW) in a 4- step process between 3 December 2018 and 
7 February 2019 on  ClinicalTrials. gov, PubMed, Google 
Scholar and Web of Science (figure 1). We defined a 
publication as an article with at least 400 words. In case 
of multiple results publications, we chose the earliest 
publication. When a study contained the results of two 
or more trials but reported the results of each trial sepa-
rately, it was included. Abstracts, study design publications 
without results, reviews and other background literature 
were excluded. If there was a disagreement whether to 
include or exclude a publication, the third person (an 
arbiter, MW) was involved. The flow chart showing the 
publication search with reasons for exclusion is presented 
in online supplementary figure 2. When a publication was 
identified, we extracted first publication date, PubMed 
ID and DOI (if applicable). Only if all searches stayed 
without results, the study was characterised as ‘no publi-
cation found’.
Paediatric trials
We classified a study as paediatric when all or most partic-
ipants (over 50%) were less than 18 years. If the study 
enrolled both adult and paediatric participants but it was 
impossible to determine whether the majority of study 
participants were above or under 18 years of age, we clas-
sified the trial as mixed population study. Unclear studies 
lacked data on average/median age of participants, thus 
it was impossible to assign them to either of these groups. 
The information on participants’ age was searched on: 
ClinicalTrials. gov website, in publications or in other 
sources such as other registries (eg, European Clinical 
Trials Register) or sponsor websites if any additional study 
identification numbers were provided on  ClinicalTrials. 
gov.
Patient and public involvement
No patient involved.
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Figure 1 Publication search strategy.
Statistical analysis
We used a logistic regression analysis to identify explan-
atory variables with a possible effect on the timely publi-
cation rates (online supplementary material). We started 
with a univariate model, testing all variables individually 
to identify the variable that leads to the largest increase in 
the log- likelihood. Then the regression model was built 
stepwise by including the variable with the largest log- 
likelihood increase in each step until there was no more 
variable that could be added to substantially increase the 
log- likelihood. There were however no strict rules for 
variable inclusion, as this was an exploratory analysis.
ReSulTS
We identified 1267 interventional clinical trials registered 
on  ClinicalTrials. gov with a CD between 2009 and 2013, 
conducted in a city with an AMC. Of these, we excluded 
962 mainly because there was no name of the AMC or the 
academic hospital, leaving 305 trials across 13 academic 
institutions enrolling 119 490 anticipated participants. 
Among the trials, 259 (84.9%) were randomised, 248 
(81.3%) were adult trials, 241 (79.0%) were multicentre 
trials, 223 (73.1%) were industry- sponsored, 209 (68.5%) 
tested drugs and 75 (24.6%) were lead trials (table 1). For 
more information, see table 1.
Results reporting
Of the 305 trials completed between 2009 and 2013, 
120 (39.3%) posted summary results on  ClinicalTrials. 
gov and 23 (7.5%) did it within 12 months after trial 
CD (table 2). Still, more than 5 years after all the trials 
ended, 175 (57.4%) have not posted their results. Among 
75 lead trials, 5 (6.7%) posted results on the registry 
website, leaving 67 (89.3%) trials without results posted 
or submitted.
Publication rates
Of the 305 trials, 218 (71.5%) had published results as 
a journal publication as of 7 February 2019 (table 2). 
Results were published before trial ended or within 2 
years of trial completion for 123 trials (40.3%). Further-
more, 57 trials (76.0%), in which Polish AMC took the 
lead published results and 39 (52.0%) did it before trial 
completed or within 2 years of study end.
Overall dissemination
Overall, 243 of the 305 trials (79.7%) had been published 
or posted their summary results (table 2). Results 
were posted within a year of study completion and/or 
published within 2 years of study completion for 131 trials 
(43.0%). Dissemination by both posting summary results 
on the registry website within a year of study CD and 
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Table 1 Characteristics of all and lead trials across 13 
Polish academic medical centres completed between 2009 
and 2013
All trials Lead trials
Total 305 100% 75 100%
Enrolled participants:
  1–100 98 32.1% 47 62.7%
  101–500 136 44.6% 22 29.3%
  501–1000 50 16.4% 3 4.0%
  >1000 20 6.6% 2 2.7%
  N/R 1 0.3% 1 1.3%
Study phase
  I 6 2.0% 2 2.7%
  I/II 4 1.3% 2 2.7%
  II 79 25.9% 6 8.0%
  II/III 13 4.3% 4 5.3%
  III 123 40.2%* 8 10.7%
  IV 42 13.8% 26 34.7%
  N/A 38 12.5% 27 35.9%*
Trial status
  Completed 241 79.0% 54 72.0%
  Terminated 40 13.1% 4 5.3%
  Unknown 24 7.9% 17 22.7%
Trial completion year
  2009 53 17.4% 9 12.0%
  2010 49 16.1% 13 17.3%
  2011 54 17.7% 17 22.7%
  2012 67 22.0% 16 21.3%
  2013 82 26.8%* 20 26.7%
Trial primary completion year
  <2009 19 6.2% 3 4.0%
  2009 55 18.0% 12 16.0%
  2010 47 15.4% 14 18.7%
  2011 54 17.7% 12 16.0%
  2012 68 22.4%* 16 21.3%
  2013 59 19.3% 17 22.7%
  N/R 3 1.0% 1 1.3%
Registration time†
  Before trial start 167 54.7%* 18 24.0%
  After trial start 103 33.8% 28 37.3%
  After trial completion 
date
32 10.5% 27 36.0%
  After publication 3 1.0% 2 2.7%
Population
  Adult 248 81.3% 50 66.7%
  Paediatric 53 17.4% 25 33.3%
  Mixed 3 1.0% 0 0.0%
  Unclear 1 0.3% 0 0.0%
Continued
All trials Lead trials
Type of intervention
  Behavioural 2 0.7% 1 1.3%
  Biological 31 10.2% 4 5.3%
  Device 25 8.2% 11 14.7%
  Dietary supplement 12 3.9% 11 14.7%
  Drug 209 68.5% 30 40.1%*
  Genetic 1 0.3% 1 1.3%
  Other 8 2.6% 6 8.0%
  Procedure 14 4.6% 9 12.0%
  Radiation 1 0.3% 1 1.3%
  N/A or N/R 2 0.7% 1 1.3%
Monocentre/multicentre
  Multicentre 241 79.0% 15 20.0%
  Monocentre 56 18.4% 53 70.7%
  N/A or N/R 8 2.6% 7 9.3%
Lead sponsor
  Industry 223 73.1% 8 10.7%
  Public 76 24.9% 63 84.0%
  Other 6 2.0% 4 5.3%
Randomisation status
  Non- randomised 17 5.6% 9 12.0%
  Randomised 259 84.9% 60 80.0%
  N/A or N/R 29 9.5% 6 8.0%
Masking
  Double blind 167 54.8% 37 49.3%
  Open label 112 36.7% 26 34.7%
  Single blind 23 7.5% 11 14.7%
  N/A or N/R 3 1.0% 1 1.3%
*The percentage was calculated by subtracting the remaining % 
values from 100%.
†Registration time was calculated using the study_first_submitted_
date and start date/completion date/publication date.
N/A, not applicable; N/R, not reported.
Table 1 Continued
publication within 2 years of study CD was achieved for 15 
trials (4.9%). The percentage of non- disseminated trials 
over time is presented in online supplementary figure 3.
Paediatric versus adult studies
There was no significant difference in dissemination of 
findings in paediatric trials compared to adult trials, 73.6% 
(95% CI 59.7% to 84.7%) vs 81.0% (95% CI 75.6% to 
85.7%), p=0.22. Among paediatric trials, 21 (39.6%) posted 
summary results on  ClinicalTrials. gov within a year of study 
completion and/or published them within 2 years of CD 
(see table 2). Among adult trials, the percentage of posted 
or published results was 43.5%. There was no significant 
difference in posting summary results within 12 months 
of CD comparing adult and paediatric trials 7.3% (95% CI 
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Table 2 Dissemination of clinical trial results following trial CD for all, lead, paediatric and adult trials
All trials Lead trials Paediatric trials Adult trials
Total 305 100% 75 100% 53 100% 248 100%
Posting summary results    
  No results posted 175 57.4% 67 89.3% 32 60.4% 140 56.5%
  Results posted 120 39.3% 5 6.7% 20 37.7% 99 39.9%
  Results submitted 10 3.3% 3 4.0% 1 1.9% 9 3.6%
Posting time on ClinicalTrials.gov among trials with results posted
  Before trial 
completion
4 1.3% 0 0.0% 1 1.9% 3 1.2%
  ≤12 months after CD 19 6.2% 1 1.3% 4 7.5% 15 6.0%
  >12 ≤ 24 months 
after CD
36 11.6%* 1 1.3% 8 15.1% 27 11.0%†
  >24 ≤ 36 months 
after CD
20 6.6% 2 2.8%‡ 4 7.5% 16 6.5%
  >36 ≤ 48 months 
after CD
17 5.6% 1 1.3% 2 3.8% 15 6.0%
  >48 ≤ 60 months 
after CD
9 3.0% 0 0.0% 1 1.9% 8 3.2%
  >60 ≤ 72 months 
after CD
6 2.0% 0 0.0% 0 0.0% 6 2.4%
  >72 months after CD 9 3.0% 0 0.0% 0 0.0% 9 3.6%
Publication found         
  Yes 218 71.5% 57 76.0% 36 67.9% 180 72.6%
  No 87 28.5% 18 24.0% 17 32.1% 68 27.4%
Where was publication 
found?
        
  ClinicalTrials.gov 144 47.2% 35 46.7% 24 45.2%§ 119 48.0%
  PubMed 8 2.6% 0 0.0% 1 1.9% 7 2.8%
  Google Scholar 64 21.0% 22 29.3% 11 20.8% 53 21.4%
  Web of Science 2 0.7% 0 0.0% 0 0.0% 1 0.4%
Publication time         
  Before trial 
completion
20 6.6% 4 5.3% 1 1.9% 18 7.3%
  ≤24 months after CD 103 33.8% 35 46.7% 19 35.8% 83 33.5%
  >24 ≤ 36 months 
after CD
52 17.0% 7 9.3% 8 15.1% 44 17.7%
  >36 ≤ 48 months 
after CD
26 8.5% 6 8.0% 3 5.7% 23 9.3%
  >48 ≤ 60 months 
after CD
8 2.6% 3 4.0% 4 7.5% 4 1.6%
  >60 ≤ 72 months 
after CD
7 2.3% 2 2.7% 1 1.9% 6 2.4%
  >72 months after CD 2 0.7% 0 0.0% 0 0.0% 2 0.8%
Pooled dissemination         
  Posting summary 
results within 12 
months¶
23 7.5% 1 1.3% 5 9.4% 18 7.3%
  Publishing results 
within 24 months¶**
123 40.3% 39 52.0% 20 37.7% 101 40.7%
Continued
 on F
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All trials Lead trials Paediatric trials Adult trials
  Posting and/or 
publishing results††
131 43.0% 39 52.0% 21 39.6% 108 43.5%
  Posting and 
publishing results‡‡
15 4.9% 1 1.3% 4 7.5% 11 4.4%
  Overall 
dissemination§§
243 79.7% 57 76.0% 39 73.6% 201 81.0%
*The percentage was calculated by subtracting the remaining % values from 39.3%.
†The percentage was calculated by subtracting the remaining % values from 39.9%.
‡The percentage was calculated by subtracting the remaining % values from 6.7%
§The percentage was calculated by subtracting the remaining % values from 67.9%.
¶Study results posted on ClinicalTrials.gov before CD or within 12 months after CD
**Study results published as a journal publication before CD or within 24 months after CD.
††Study results posted on ClinicalTrials.gov before CD or within 12 months after CD and/or published as a journal publication before CD or 
within 24 months after CD.
‡‡Study results posted on ClinicalTrials.gov before CD or within 12 months after CD and published as a journal publication before CD or 
within 24 months after CD.
§§Study results posted and/or published as of 7 February 2019.
CD, completion date.
Table 2 Continued
Table 3 Dissemination of clinical trial results following trial primary completion date for all, lead, paediatric and adult trials
All trials Lead trials Paediatric trials Adult trials
Total 305 100% 75 100% 53 100% 248 100%
Timely dissemination:       
Posting summary results within 12 months of PCD* 12 3.9% 1 1.3% 4 7.5% 8 3.2%
Publishing results within 24 months of PCD† 102 33.4% 33 44.0% 18 34.0% 82 33.1%
Posting and/or publishing results‡ 110 36.1% 34 45.3% 20 37.7% 88 35.5%
Posting and publishing results§ 4 1.3% 0 0.0% 2 3.8% 2 0.8%
All the percentages calculated on the total numbers for all, lead, paediatric or adult trials.
*Study results posted on ClinicalTrials.gov within 12 months after PCD.
†Study results published as a journal publication before PCD or within 24 months after PCD.
‡Study results posted on ClinicalTrials.gov within 12 months after PCD and/or published as a journal publication before PCD or within 24 
months after PCD.
§Study results posted on ClinicalTrials.gov within 12 months after PCD and published as a journal publication before PCD or within 24 
months after PCD.
PCD, primary completion date.
4.4% to 11.2%) vs 9.4% (95% CI 3.1% to 20.7%), p=0.80; 
neither in disseminating results by both posting them on 
the website and publication 4.4% (95% CI 2.2% to 7.8%) 
for adult vs 7.5% (95% CI 0.4% to 14.7%) for paediatric 
trials, p=0.55.
Timely dissemination
In table 3, we presented results in the light of the WHO 
criteria of timely dissemination.15 Of the 305 investiga-
tional clinical trials completed between 2009 and 2013 
across Polish AMCs, four trials (1.3%) would meet both 
criteria to post summary result within 12 months of primary 
study completion and publish them as a journal publica-
tion within 24 months of study completion. For lead trials, 
neither of 75 trials would meet these both criteria.
Dissemination rates between academic institutions
Rates of results reporting within 12 months of PCD 
ranged from 0.0% (0/60) to 16.0% (4/25) across 
AMCs (table 4). The proportion of clinical trials with 
results published within 24 months of PCD ranged from 
0.0% (0/1) to 58.3% (14/24). Rates of trials meeting 
both criteria of timely dissemination ranged from 0.0% 
(0/60) to 8.0% (2/25). The overall rate of dissemina-
tion across institutions ranged from 72.1% (31/43) to 
100% (9/9).
Subgroup analyses
Only the variable ‘phase’ lead to a strong reduction in 
the log- likelihood in the logistic regression model (see 
online supplementary material). The effect of the ‘phase’ 
variable on timely reporting was as the following: while 
the early phase trials (especially phase 2) had low timely 
publication rates (24% for phase 2), the later phase trial 
publication rates were on average above 50% (55% for 
phase 3, 62% for phase 4).
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DISCuSSIOn
Our cross- sectional analysis of all Polish AMCs revealed low 
performance rates for timely disseminating the findings 
of interventional clinical trials completed between 2009 
and 2013. Only 36.1% (110/305) of trials were published 
as a journal article within 2 years of primary study comple-
tion or reported results on  ClinicalTrials. gov within a year 
of PCD. Still 20.3% (62/305) of trials remain without 
their results disseminated. Delayed dissemination and 
non- dissemination of trial results, among others, nega-
tively affect decisions in healthcare and leave recruited 
participants without information whether the therapy 
actually works or not.26 Posting summary results on the 
registry website allows the research findings to be acces-
sible to everyone. Moreover, the results are presented 
in the same format, which reduces reporting bias and 
limitations arising from journals’ various requirements 
on maximum number of tables or article length. Despite 
the fact, that sharing study results via  ClinicalTrials. gov is 
not as complicated and time consuming as publishing a 
peer- reviewed journal article, our analysis showed that the 
rates of timely reporting of summary results in the clin-
ical trial registry had been particularly low between Polish 
AMCs, ranging from 0.0% across 4 Polish AMCs to 16.0% 
(Ludwik Rydygier Collegium Medicum in Bydgoszcz). 
Overall, 3.9% (12/305) of all trials and 1.3% (1/75) of 
lead trials had met the criterion of posting the trial find-
ings in the results section of the clinical trial registry within 
12 months of primary study completion.15 16 18 Other 
research confirms such low reporting rates.20–25 This 
may be due to researchers’ anxiety that posting summary 
results in the results section on  ClinicalTrials. gov will 
deprive them the chance to publish the same results in 
the journal. Another possible reason is that researchers 
in academia are required to publish in peer- reviewed 
journals and not necessarily in registries and databases. 
These could be improved by various initiatives at AMCs 
motivating researchers to disseminate results more 
broadly. Another solution that could increase reporting 
in the clinical trial registry would be that all journals do 
not accept for publication unregistered trials and trials 
without their results at least submitted. Moreover, study 
sponsors should enforce timely results reporting.27 When 
a principal investigator applies for new funding, they 
may be asked to provide a list of all previous trials and 
their reporting status.15 The motivation to disseminate 
the study results may be also the effect of the extensive 
actions such as public debate, training, conferences, pres-
sure from the scientific community and other. AMCs may 
also formulate clear and efficient rules that will apply to 
the persons responsible for disseminating the results of 
the research.
Despite the broad consensus that all research results 
should be disseminated, a suggested scope and suggested 
dissemination time varies.11 13 15–19 Thus in our study we 
provided the rates of results dissemination following both 
the study’s primary CD (PCD) and CD. We found that 
rates of reporting of results following CD are as low as the 
rates of results reporting following PCD.
We decided to analyse the dissemination results in 
paediatric trials separately because of a special status of 
the paediatric population. These trials are required to 
offer an additional protection by imposing a strict risk 
threshold or allowing paediatric research only when there 
is a prospect of direct benefit for the participants. The 
ethical justification of trials with vulnerable populations 
hinges also on a social value they are able to offer, that is, 
the ability to provide generalisable scientific and medical 
knowledge. If the results of a trial are not available publicly, 
the trial has no way of providing generalisable knowledge 
or changing clinical practice, thus robbing the trial of its 
social value component. Our analysis showed that there 
was no significant difference in dissemination of results 
between paediatric and adult trials.
Our analysis has several limitations. First, we searched 
ClinicalTrials. gov instead of EU Clinical Trials Register 
as it contained more registered clinical trials conducted 
in Poland in a specific search period. Thus, we possibly 
not included a fraction of trials registered only at the EU 
Clinical Trials Register. Second, our results may be under-
estimated as in 2009–2013 about 450 new clinical trials 
were conducted in Poland annually for both academic 
and non- academic sites, giving a total of 2243 new clin-
ical trials over 5 years.28 We captured 1267 completed 
trials and excluded almost 76% of them mainly because 
the name of the research site was not provided (also see 
online supplementary figure 1). Third, we relied on the 
recruitment status found in the database which might not 
had been updated, meaning that some active or recruiting 
trials could in fact be completed.29 We also relied on the 
names of AMCs and teaching hospitals provided on the 
website. We added the city name as the additional search 
criterion to include all studies conducted by AMCs to 
avoid misspellings of names and shortcuts on  Clinical-
Trials. gov. We classified studies as lead trials only when 
it was clearly reported that AMC was a lead contributor 
in the trial. If there was a name of the teaching hospital 
without the AMC name, the trial was then considered as 
a facility trial. Fourth, we did not asses the accuracy of 
the dates of study start and completion in the  Clinical-
Trials. gov database. In some clinical trials the reporting 
of results and publication dates preceded the PCD and 
CD. We counted those results as reported within a year 
of study completion which may overestimate our results. 
Fifth, we defined publication as an article with at least 
400 words. Such publication may be only a hint that such 
a study was conducted and may not demonstrate full 
methodology and results. Nevertheless, every journal has 
different requirements, word and table limits; therefore, 
it is challenging to present entire study results of large 
multicentre trials. There is also a well- known problem of 
the selective results reporting.30 Sixth, despite extensive 
publication search by two researchers independently we 
could have missed some relevant publications. Seventh, 
we did not assess the quality of results reporting and we 
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did not compare protocols and outcomes, we also did 
not assess the consistency of results reporting in the 
ClinicalTrials. gov database compared to those published 
in journal publications. Finally, we could follow trials 
completed in 2009 for more than 9 years whereas trials 
competed in 2013 we could follow only for 5 years.
COnCluSIOn
Our cross- sectional analysis revealed that Polish AMCs fail 
to meet the expectation for timely disseminating the find-
ings of all interventional clinical trials. Despite the fact, 
that eventually about 80% trial results were disseminated, 
some of them are hard to find, for example, published in 
non- indexed journals or not linked clearly with National 
Clinical Trial (NCT) identifier number. Overall dissemina-
tion rates outperformed the rates in similar studies in the 
USA and Germany.19 23 Nevertheless, timely reporting on 
the registry still remains very poor and the dissemination 
by both posting and publishing results was achieved by 
four trials (1.3%). Our findings illustrate that after quite 
successful efforts in promoting a timely dissemination 
among industry, it is time to urge AMCs and other public 
institutions to fulfil this important ethical requirement.
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